SLC5A2 and Hypervolemia: The focus is primarily on clinical data from observational and randomized studies that assess the impact of SGLT-2 inhibitors on decongestion in patients with fluid overload and symptom improvement and secondarily on the safety profile and potential adverse effects associated with SGLT-2 inhibitor use in decompensated HF.